文章核心观点 Pharvaris宣布其摘要被三个即将召开的大会接受展示，涵盖多项关于遗传性血管性水肿（HAE）和C1抑制剂缺乏性获得性血管性水肿（AAE - C1INH）等疾病的研究成果 [1] 会议信息 14th C1 - Inhibitor Deficiency and Angioedema Workshop（布达佩斯，2025年5月29 - 6月1日） - 标题“Clinical Validation of a Novel Biomarker Assay to Characterize Bradykinin - Mediated Angioedema in Prospective and Biobank Plasma Samples”，演讲者Evangelia Pardali博士，形式为口头报告，时间为5月30日8:45 - 9:00 CEST [2] - 标题“Long - Term Prophylactic Treatment With Oral Deucrictibant Improves Health - Related Quality of Life and Disease Control in Participants With Hereditary Angioedema: CHAPTER - 1 Open - Label Extension Study”，演讲者Markus Magerl医学博士，形式为海报展示，时间为5月30日15:45 - 17:30 CEST [2] - 标题“Sustained Therapeutic Exposure with Once - Daily Oral Deucrictibant XR Tablet for Prophylaxis of Hereditary Angioedema Attacks: Results of a Pharmacokinetics Study in Healthy Volunteers”，演讲者Zhi - Yi Zhang博士，形式为海报展示，时间为5月30日15:45 - 17:30 CEST [2] - 标题“Acquired Angioedema Due to C1 - Inhibitor Deficiency: Patient Experience and Assessment of Patient - Reported Outcome Measures”，演讲者Andrea Zanichelli医学博士、博士，形式为海报展示，时间为5月30日15:45 - 17:30 CEST [2] - 标题“Long - Term Safety and Efficacy of Oral Deucrictibant for Prophylaxis in Hereditary Angioedema: Data Snapshot Results of the CHAPTER - 1 Open - Label Extension Study”，演讲者Emel Aygören - Pürsün医学博士，形式为口头报告，时间为5月31日15:30 - 15:45 CEST [2] - 标题“Long - Term Safety and Efficacy of Oral Deucrictibant for Treatment of Hereditary Angioedema Attacks: Results of the RAPIDe - 2 Extension Study”，演讲者Marc A. Riedl医学博士、理学硕士，形式为口头报告，时间为5月31日15:45 - 16:00 CEST [2] - 标题“Durability Of Response to a Single Dose of Oral Deucrictibant for On - Demand Treatment of Hereditary Angioedema Attacks”，演讲者Anna Valerieva医学博士、博士，形式为海报展示，时间为5月31日16:45 - 17:45 CEST [2] - 标题“CHAPTER - 3 Phase 3 Trial Design: Efficacy and Safety of the Oral Bradykinin B2 Receptor Antagonist Deucrictibant Extended - Release Tablet for Prophylaxis of Hereditary Angioedema Attacks”，演讲者Andrea Zanichelli医学博士、博士，形式为海报展示，时间为5月31日16:45 - 17:45 CEST [2] - 标题“Safety and Efficacy of Oral Deucrictibant for Treatment of Upper Airway and Laryngeal Hereditary Angioedema Attacks: Results from the RAPIDe - 2 Extension Study”，演讲者Ramón Lleonart医学博士，形式为海报展示，时间为5月31日16:15 - 17:45 CEST [2] - 标题“Epidemiology of Bradykinin - Mediated Angioedema in the European Population”，演讲者Emel Aygören - Pürsün医学博士，形式为海报展示，时间为5月31日16:15 - 17:45 CEST [3] 2025 Eastern Allergy Conference（佛罗里达州棕榈滩，2025年5月29 - 6月1日） - 未提及具体展示内容 [4] European Academy of Allergy and Clinical Immunology (EAACI) Congress 2025（格拉斯哥，2025年6月13 - 16日） - 标题“Long - Term Safety and Efficacy of Oral Deucrictibant for Prophylaxis in Hereditary Angioedema: Results of the CHAPTER - 1 Open - Label Extension Study”，演讲者Markus Magerl医学博士，形式为快速演讲（电子海报），时间为6月15日14:00 - 15:30 BST [6] - 标题“Long - Term Safety and Efficacy of Oral Deucrictibant for Treatment of Hereditary Angioedema Attacks: Results of the RAPIDe - 2 Extension Study”，演讲者John Anderson医学博士，形式为海报展示，时间为5月30日9:45 - 11:00 a.m. ET [6] - 标题“Clinical Validation of a Novel Kinin Biomarker Assay for Characterization of Bradykinin - Mediated Pathologies in U.S. Subjects with Hereditary Angioedema”，演讲者Evangelia Pardali博士，形式为快速演讲（电子海报），时间为6月13日13:15 - 14:45 BST [6] - 标题“Long - Term Safety and Efficacy of Oral Deucrictibant for Prophylaxis in Hereditary Angioedema: Results of the CHAPTER - 1 Open - Label Extension Study”，演讲者Emel Aygören - Pürsün医学博士，形式为专题海报会议，时间为6月14日12:00 - 13:00 BST [6] - 标题“Long - Term Safety and Efficacy of Oral Deucrictibant for Treatment of Hereditary Angioedema Attacks: Results of the RAPIDe - 2 Extension Study”，演讲者Henriette Farkas医学博士、博士、理学博士，形式为专题海报会议，时间为6月14日12:00 - 13:00 BST [6] - 标题“Development of a Conceptual Model Supporting a Clinical Outcome Assessment Strategy for Acquired Angioedema due to C1 Inhibitor Deficiency”，演讲者Andrea Zanichelli医学博士、博士，形式为专题海报会议，时间为6月15日12:45 - 13:45 BST [6] - 标题“Safety and Efficacy of Oral Deucrictibant for Treatment of Upper Airway and Laryngeal Hereditary Angioedema Attacks: Results from the RAPIDe - 2 Extension Study”，演讲者Anna Valerieva医学博士、博士，形式为快速演讲（电子海报），时间为6月15日14:00 - 15:30 BST [6] - 标题“CHAPTER - 3 Phase 3 Trial Design: Efficacy and Safety of the Oral Bradykinin B2 Receptor Antagonist Deucrictibant Extended - Release Tablet for Prophylaxis of Hereditary Angioedema Attacks”，演讲者William Lumry医学博士，形式为快速演讲（电子海报），时间为6月15日14:00 - 15:30 BST [6] - 标题“Long - Term Prophylactic Treatment with Oral Deucrictibant Improves Disease Control and Health - Related Quality of Life in Participants with Hereditary Angioedema in the CHAPTER - 1 Open - Label Extension Study”，未提及具体演讲者、形式和时间 [6] - 标题“Health - Related Quality of Life and Clinical Characteristics in People Living with Hereditary Angioedema Prescribed Long Term Prophylaxis Alone and On - Demand Treatment Alone”，演讲者Laurence Bouillet医学博士、博士，形式为口头报告，时间为6月15日15:45 - 17:15 BST [7] 公司信息 - 公司是一家后期生物制药公司，开发新型口服缓激肽B2受体拮抗剂，旨在解决缓激肽介导的血管性水肿未满足的需求 [1][8] - 公司计划提供类似注射剂的疗效和类似安慰剂的耐受性，通过口服疗法预防和治疗缓激肽介导的血管性水肿发作 [8] - 公司在HAE的2期预防和按需治疗研究中取得积极数据，目前正在评估deucrictibant在预防HAE发作的关键3期研究（CHAPTER - 3）和按需治疗HAE发作的关键3期研究（RAPIDe - 3）中的疗效和安全性 [8]